Gilead Sciences, Inc. (NASDAQ:GILD) Position Trimmed by Johnson Investment Counsel Inc.

Johnson Investment Counsel Inc. trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 24,280 shares of the biopharmaceutical company’s stock after selling 252 shares during the period. Johnson Investment Counsel Inc.’s holdings in Gilead Sciences were worth $1,672,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Kempen Capital Management N.V. boosted its holdings in Gilead Sciences by 4.3% during the first quarter. Kempen Capital Management N.V. now owns 360,584 shares of the biopharmaceutical company’s stock worth $23,304,000 after buying an additional 14,814 shares in the last quarter. Brandes Investment Partners LP lifted its position in shares of Gilead Sciences by 33.5% in the 1st quarter. Brandes Investment Partners LP now owns 30,924 shares of the biopharmaceutical company’s stock valued at $2,026,000 after acquiring an additional 7,765 shares in the last quarter. Lido Advisors LLC lifted its position in shares of Gilead Sciences by 53.0% in the 1st quarter. Lido Advisors LLC now owns 46,168 shares of the biopharmaceutical company’s stock valued at $2,984,000 after acquiring an additional 15,994 shares in the last quarter. Clearbridge Investments LLC lifted its position in shares of Gilead Sciences by 149.8% in the 1st quarter. Clearbridge Investments LLC now owns 1,714,612 shares of the biopharmaceutical company’s stock valued at $110,815,000 after acquiring an additional 1,028,302 shares in the last quarter. Finally, Manning & Napier Group LLC lifted its position in shares of Gilead Sciences by 16.1% in the 2nd quarter. Manning & Napier Group LLC now owns 486,157 shares of the biopharmaceutical company’s stock valued at $33,476,000 after acquiring an additional 67,578 shares in the last quarter. Hedge funds and other institutional investors own 78.04% of the company’s stock.

Several equities research analysts recently commented on GILD shares. BMO Capital Markets upped their price target on shares of Gilead Sciences from $67.00 to $72.00 and gave the company a “market perform” rating in a research report on Friday, July 30th. Morgan Stanley increased their target price on shares of Gilead Sciences from $83.00 to $84.00 and gave the stock an “overweight” rating in a research report on Tuesday. Oppenheimer started coverage on shares of Gilead Sciences in a research report on Monday, June 28th. They issued a “buy” rating and a $100.00 target price for the company. Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating and set a $72.00 target price for the company in a research report on Tuesday, August 10th. Finally, SVB Leerink increased their target price on shares of Gilead Sciences from $74.00 to $77.00 and gave the stock an “outperform” rating in a research report on Friday, July 30th. Eight research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences has an average rating of “Buy” and a consensus price target of $105.72.

In other Gilead Sciences news, CAO Diane E. Wilfong sold 13,610 shares of the firm’s stock in a transaction on Tuesday, August 17th. The shares were sold at an average price of $72.50, for a total value of $986,725.00. Following the sale, the chief accounting officer now directly owns 30,179 shares in the company, valued at approximately $2,187,977.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.12% of the company’s stock.

NASDAQ:GILD opened at $67.63 on Thursday. Gilead Sciences, Inc. has a 1 year low of $56.56 and a 1 year high of $73.34. The firm’s fifty day simple moving average is $70.59 and its 200 day simple moving average is $68.42. The company has a current ratio of 1.36, a quick ratio of 1.19 and a debt-to-equity ratio of 1.42. The firm has a market capitalization of $84.80 billion, a PE ratio of 16.50, a PEG ratio of 0.63 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, July 29th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.76 by $0.11. The business had revenue of $6.22 billion for the quarter, compared to analyst estimates of $6.15 billion. Gilead Sciences had a net margin of 19.38% and a return on equity of 55.94%. During the same period last year, the business posted $1.11 EPS. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.15 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 29th. Shareholders of record on Wednesday, September 15th were given a $0.71 dividend. The ex-dividend date of this dividend was Tuesday, September 14th. This represents a $2.84 annualized dividend and a yield of 4.20%. Gilead Sciences’s dividend payout ratio is 40.06%.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Featured Article: Why is the price-sales ratio important?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.